

By the Barcelona chapter of ACG,
the international Association for Corporate Growth

Reig Jofre awarded best corporate transaction in 2014 for its merger with Natraceutical

Sant Joan Despi, Barcelona (Spain), March 10, 2015. The merger between Reig Jofre and Natraceutical was awarded by ACG Barcelona as best corporate transaction of 2014 in Catalonia. The distinction rewards companies that contribute to the development of the M & A market.

ACG (Association for Corporate Growth), the largest global community of entrepreneurs and professionals in the corporate world, whose main purpose is to foster the growth of both its members and the corporations to which they belong, recognized through this award the merger that resulted in the fifth Spanish pharmaceutical company quoted on the stock exchange.

The event, which was held yesterday at ESADE Business School, was chaired by Felip Puig, Minister of Enterprise and Employment of the Catalan government. Gas Natural Fenosa and Mat Holding were awarded as finalists for the purchase of CGE Group (General Electric Company) and the purchase of 100% of Dorot, respectively.

Diversification of the portfolio and strengthening of international presence

With sales of 152.5 million euros according to proforma data of 2014 after the merger, the new Reig Jofre is fully vertically integrated and has strengthened its market position by diversifying its product portfolio in pharma, OTC, and nutritional supplements, as well as its international presence, with a turnover outside Spain of 60% and commercial presence in over 50 countries on five continents.

The complementarity in the mentioned fields will allow a significant improvement in Reig Jofre's revenues and margins, thus increasing its profitability and enhancing its strong business and financial structure.



Advisors to the former Reig Jofre were: Solventis (financial advisors), Rousaud Costas Duran (legal advisors) and KPMG (auditors), and to Natraceutical: N+1 (financial advisors), Garrigues (legal advisors) and PwC (auditors). Additionally, EY conducted the due diligence and made the report on the industrial sense of the operation and BDO was in charge of the independent valuation for the exchange ratio.

The new company constituted the board of directors at the beginning of 2015 and appointed Ignasi Biosca Reig as CEO. The board of the new Reig Jofre has got five independent directors with a sound professional experience in the pharmaceutical industry, scientific research, finance and capital markets, internationalization, marketing and advertising.

Since the merger was registered in the Commercial Registry on December 31, 2014, Reig Jofre's shares raise by 67%, which places the market cap of the company at 388 million euros.

About Reig Jofre

After the merger between Laboratorio Reig Jofre and Natraceutical, the new Reig Jofre is a pharmaceutical company whose business is divided into two major areas: one main for the development, manufacture and marketing of own products (approximately 73% of sales) and one of specialized manufacturing for thirds (27% of sales). At its core activity, the company specializes in the development of prescription and non-prescription pharmaceutical products, generics based on specialized technologies, medical devices, nutritional supplements and cosmetics. The company directs its R&D to develop new indications and/or dosage forms of known active principles, generics with special focus on beta lactam and lyophilized injectable antibiotics, topical dermatological products, OTCs and nutritional supplements as well as the development of new innovative molecules in partnership with start-ups and research centers.

Reig Jofre trades on the Spanish stock exchange under the ticker RJF. Total outstanding shares: 1,264,284,408

For further information

Media

Ricardo Franco - Inforpress
Tel. +34 93 419 06 30 - rfranco@inforpress.es

Investors and analysts

Gloria Folch - Head of Investor Relations - Reig Jofre
Tel. +34 93 584 81 85 - gloria.folch@reigjofre.com